FDA approves Boehringer' Ofev to treat idiopathic pulmonary fibrosis

October 16, 2014 7:56 AM

6 0

The US Food and Drug Administration has approved Boehringer Ingelheim Pharmaceuticals' Ofev (nintedanib) capsules to treat idiopathic pulmonary fibrosis (IPF).

Ofev is a kinase inhibitor that blocks multiple pathways that may be involved in the scarring of lung tissue and these capsules will be available to patients within 10 days, the company said.

Read more

To category page

Loading...